following variables were identified as predictors of poor image quality in descending order of frequency: BSL valve (Odds 3.5 IC 95% [1.3 -9.6], p¼0.02), presence of an artifact (Odds 2.5 IC 95% [1.2 -5.4], p¼0.02) and BMI (Odds 1.1 IC 95% [1.0 -1.2], p¼0.04).
BACKGROUND Stroke is a feared complication of trans-catheter aortic valve replacement (TAVR). Carotid and vertebral artery duplex ultrasonography is routinely obtained prior to TAVR, but the significance of extracranial carotid and vertebral artery disease (CVD) on the risk of stroke following TAVR is unknown. The purpose of this study is to assess the impact of CVD on the risk of stroke following TAVR.
METHODS We reviewed 294 consecutive cases of TAVR at a single tertiary care academic medical center from June, 2008 to March, 2015 We included 263 patients who underwent routine carotid and vertebral artery duplex ultrasonography prior to TAVR in a retrospective cohort study. Patients with at least 50% stenosis of a carotid or vertebral artery were identified as having CVD, and patients were stratified into 2 groups by the presence or absence of CVD. The primary outcome was stroke within 30 days of TAVR. We adjudicated stroke by the guideline recommendations of the Valve Academic Research Consortium. Secondary outcomes included 30-day mortality and overall survival following TAVR. We used chi2 and Fischer's exact tests to compare categorical variables and independent samples t tests to compare continuous variables. We used Kaplan Meier life table analysis to assess overall survival. We included univariate predictors of stroke at P<0.10 in a multivariable logistic regression to identify predictors of stroke after TAVR.
RESULTS CVD was present in 51 (19%) patients. The CVD group had higher rates of coronary artery disease, prior coronary artery bypass surgery, and peripheral artery disease compared to the non-CVD group. There was no significant difference in the rate of prior stroke or the burden of aortic atheroma by intra-operative trans-esophageal echocardiogram between CVD and non-CVD patients. Trans-femoral access was less common in the CVD group (55% vs. 77%, p<0.01). Stroke occurred in 18 (6.8%) patients within 30 days after TAVR. No patients with CVD suffered a stroke. There was no difference in 30day mortality (10% vs 4%, p¼0.11) and overall survival (log-rank test, p¼0.89) between the CVD and non-CVD groups. CVD was not a significant predictor of stroke following TAVR by logistic regression. In a multivariable model, there were no significant independent predictors of stroke after TAVR, but baseline antiplatelet therapy showed a trend towards a protective effect, and higher pre-TAVR mean aortic valve gradient showed a trend toward increased risk of stroke (table) . METHODS We screened 400 patients with severe aortic stenosis who were referred for TAVR between 2010-2014 who had had multi-detector computed tomographic (MDCT) imaging. Annulus measurements of the basal ring (short-and long-axis, area-derived diameter), coronary ostia height, sinus area (SA), sino-tubular junction area (STJ), calcification and eccentricity index (EI, 1-short axis/long axis) were made.
Predictors of Stroke

RESULTS
The vast majority of patients were able to be offered a currently available TAVR valve (88%). We identified 49 patients who were excluded for anatomical annular characteristics alone. Large aortic annuli were the most common reason for anatomical exclusion [704 AE 79 mm2; (n¼ 39, 80 %)]. In addition these large annuli were more elliptical (EI, 1.39 AE 0.1) with more eccentric calcification (68 %). The presence of low coronary heights (n¼6 mm: n¼19, 18 %) from the aortic annular plane was the next most common reason. The left main coronary artery was more commonly lower than the right coronary artery and low coronary heights with effaced coronary sinuses appeared occur together (n¼11, 57 %). Small aortic annuli were the least common [290 AE 50 mm2; n¼1, 2 %) cause for exclusion from TAVR therapy. None of the patients who were excluded form TAVR therapy had more than one annular reason for TAVR exclusion.
CONCLUSIONS Most patients with severe aortic stenosis who are referred for TAVR can be offered a transcatheter valve. However, 12 % of patients cannot be offered a therapy due to annular anatomical exclusion criteria. This was primarily due to the presence of large aortic annuli and low coronary heights. Mini-Cognitive Assessment for Dementia). All (11/11) patients were successfully implanted with a Lotus Valve with no procedural mortality. All patients remained alive at 2 years, and the 2-year clinical follow-up and TTE assessment rates were 100% (11/11). Major stroke occurred in 1 patient on day 3, for a 2-year major stroke rate of 9.1%, and life-threatening/disabling bleeding occurred in 2 patients for a 2-year rate of 18.2%. Conduction disturbance requiring new permanent pacemaker implantation remained at 4 patients. There were no repeat hospitalizations for valve-related symptoms or cardiac decompensation. Mean aortic gradient was 15.5AE4.4mmHg and mean effective orifice area was 1.51AE0.19cm 2 at 2 years. All (100%) patients remained in New York Heart Association Class I or II. Core laboratory adjudicated paravalvular aortic regurgitation was not evaluable in 1 patient, trace/ trivial in 1 patient, mild in 1 patient, and absent in 8 patients at 2 years.
CONCLUSIONS Two-year feasibility results suggest that the Lotus Valve has minimal aortic regurgitation and low clinical event rates sustained through 2 years. Three-year outcomes from REPRISE I will be available for presentation for the first time at TCT 2015.
CATEGORIES STRUCTURAL: METHODS Between November 2008 and April 2015, a temporary permanent pacemaker system was implanted in 108 consecutive TAVI patients. An active-fixation right-ventricular lead was implanted in either an apical or septal position via the right internal jugular vein using a 7 French peel-away introducer sheet. Pacing treshold was considered acceptable if <1.0 V at a pulse width of 0.5 ms, as were Rwave sensing amplitudes > 10 mV. The lead was then sutured to the patient's neck and connected to a re-usable permanent pacemaker programmed in VVI mode. Finally, the pacemaker and lead were taped to the patient's skin in typical infraclavicular position.
RESULTS Mean patients' age was 81.1 AE 4.9 years and mean duration of TPPM was 5.6 AE 2.1 (range 2-14) days. After successful primary implantation in all patients without any procedure-related complications defined as pneumothorax, pericardial effusion with hemodynamic relevance and local infection or hematoma, lead dislocation and necessity of lead repositioning occurred in one patient (0.92%).
